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I. Medicinal chemistry 
A. History of drug discovery – privileged structures 
2 | Part 1: Introduction 
“In general, the libraries were produced with an eye towards overall quantity, 
rather than quality.”4 
privileged 
structures
“are capable of providing useful ligands for more than one receptor and that 
judicious modification of such structures could be a viable alternative in the 
search for new receptor agonists and antagonists.”7  
B. Drug-likeness vs. lead-likeness 
In vitro
I. Medicinal Chemistry | 3 
“Poor absorption or permeation are more likely when:  
There are more than 5H-bond donors; 
The molecular weight is over 500;  
The clogP is over 5; 
There are more than 10 H-bond acceptors.” 
“a molecular weight lower than 300;  
the number of H-bond donors and acceptors for both is lower or equal to three;  
a clogP value is smaller than three.” 12 
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I.2 I.3
Figure I-1:Natural compound asperlicin (I.1) and its composed elements suggested by Evans 
I.2 I.4 I.5 I.6
I.7 I.8 I.9
Figure I-2: Sternbach’s initial library of benzodiazepines 
I. Medicinal Chemistry | 5 
I.10
I.10 I.11 K




Figure I-3: Examples of the 1,4-benzodiazepine framework as privileged structure I.11 - I.19 
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Figure I-5: Examples of the 1,4-benzodiazepin-2,5-dione framework as privileged structure I.24 – I.27 
I.28
I.29 I.30
Figure I-6: 2,3-Benzodiazepine I.28 and isosteric replacement of benzene moieties I.29 – I.30 
D. Privileged structures based on natural products 
I.31
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“the natural product-like compounds produced in diversity oriented synthesis 
have a much better shot at interacting with the desired molecular targets and 
exhibiting interesting biological activity.”3  






Staphylococcus aureus Staphylococcus aureus










Figure I-9: Other examples of natural product-based libraries 
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Figure II-1: Conventional synthesis 
via
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Figure II-2
Figure II-2: Combinatorial synthesis 
Figure II-2
n m
one compound one vessel parallel 
synthesis split-mix
one compound – one 
vessel
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Figure II-3: Split-mix or split-poolmethod 
B. Solid-phase chemistry 
“I have never been able to reconstruct the moment when the idea came to me, 
but probably it was at night, just as other ideas often come into one’s head. It 
was obviously a result of having recognized a direct need and having thought 
about the general problems for some weeks. ... Although I cannot recall the 
exact time I had the idea, I do know when I recorded the basic concept in my 
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“the stepwise addition of protected amino acids to a growing peptide chain 
which is bound by a covalent bond to a solid resin particle. This provides a 
procedure whereby reagents and by-products are removed by filtration, and the 






Figure II-4: Schematic representation of a solid-phase structure. 
1. Solid support 
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a) Microscopic structure and morphology 
vide infra
b) Cross-linking and matrix structure 
 - 
via
c) Polymer-solvent compatibility 
Table II-1
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d) Polymer-substrate compatibility 
e) Presence of attachment points 
Table II-1: Swelling properties for four resins (volume in mL/g dry resin) 
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2. Linkers 
a) Linker as a bifunctional protecting group 
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Figure II-5: Overview of linker strategies 
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III. Bioisosterism 
A. Introduction  
"The properties of elements are the periodic function of their atomic masses” 
             Dmitri Mendeleev 
periodic system
molecular number N 
NA= aN1 + bN2 + … + zNi 
N N N N
a b c z
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isosterism
“Comolecules are thus isosteric if they contain the same number and 
arrangement of electrons. The comolecules of isosteres must, therefore, contain 
the same number of atoms. The essential differences between isosteres are 
confined to the charges on the nuclei of the constituent atoms.” 3 
Table III-1
Physarum polycephalum
Table III-1: Groups of isosteres as identified by Langmuir 
Groups Isosteres 
hydride displacement law:
“Atoms anywhere up to four places in the periodic system before an inert gas 
change their properties by uniting with one to four hydrogen atoms, in such a 
manner that the resulting combinations behave like pseudoatoms, which are 
similar to elements in the groups one to four places respectively, to their right.”6 
hydride
III. Bioisosterism | 27 
Table III-2
Table III-2: Grimm's Hydride Displacement Law 
Groups of pseudoatoms 
 “isosteres are atoms, ions and molecules in which the peripheral layers of 
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Table III-3: Isosterism by Erlenmeyer 
No. of peripheral electrons  
 
Figure III-1: Benzene and 
thiophene act as ring equivalents 
bioisosteres
“atoms and molecules which fit the broadest definition of isosteres and have the 
same type of biological activity” 10 
“Bioisosteres are groups or molecules which have chemical and physical 
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Figure III-3: Example of bioisosteric replacement in the benzodiazepine series 
scaffold hopping
cis
B. Triazoles as non-classical bioisosteres 
30 | Part 1: Introduction  
(vide infra)









Figure III-4: Structural and electronic evaluation of a trans-amide bond versus the 1,4-regioisomer of a 
1,2,3-triazole moiety 





Figure III-5: Structural and electronic evaluation of a cis-amide bond versus the 1,5-regioisomer of a 
1,2,3-triazole moiety 
2. 1,2,3-Triazoles as bioisosteres of double bonds 





Figure III-6: Combrestation A-1 (III.5),  A-4 (III.6) and 1,5-disubstituted 1,2,3-triazole analogues III.7-
III.9. 
32 | Part 1: Introduction  
3. Bioisosteric applications of 1,4-disubstituted 1,2,3-triazoles 







activity IC50 [mM]a 
III.10 
III.11 
Figure III-7: Cyclotetrapeptide cyclo-[Pro-Val-Pro-Tyr] (III.10) and triazole analogue III.11. 
b) Peptide bond surrogates 
III.12 III.13
III.14
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Figure III-8: Amprenavir (III.12, HIV-1 protease inhibitor) and two active peptide surrogate analogues 
c) Linkers 
d) Bioconjugation 
4. Bioisosteric applications of 1,5-disubstituted 1,2,3-triazoles 
a) Locking the configuration 
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Figure III-10: dUTPase inhibitors enhancement by including 1,5-disubstituted triazoles as cis-lock 





Figure III-11: Controlling peptide conformation by employing 1,5-disubstituted 1,2,3-triazole moieties. 
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IV. Click chemistry 
A. Introduction 
“the reaction must be modular, wide in scope, give very high yields, generate 
only inoffensive byproducts that can be removed by nonchromatographic 
methods, and be stereospecific. The required process characteristics include 
simple reaction conditions, readily available starting materials and reagents, 
the use of no solvent or a solvent that is benign (such as water) or easily 
removed, and simple product isolation”1. 
“cream of the crop”1. 
1,3-dipolar 
cycloadditions.
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hot topic
Figure IV-1: Overview of the most important click chemistry procedures 
B. CuAAC 
1. Mechanism 
IV. Click Chemistry | 41 
Scheme IV–1






Scheme IV–1: Mechanism of the CuAAC proposed by Sharpless6 and adjusted according to Fokin8 




Figure IV-2: Energy diagram of the key bond making steps in the CuAAC.6 
IV. Click Chemistry | 43 







Figure IV-3: N,N-diisopropyl-2-diphenylphosphinobenzamide (IV.9) as proposed ligand to AgOAc by 
Vemula mediating AgAAC. 







IV.4 IV.12 A IV.13 B
C
IV.14
IV.15 D IV.10  
IV.11
C
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Scheme IV–2: Mechanism of RuAAC proposed by Fokin15 
IV.16 Scheme IV-4
Figure IV-4: Four distinct situations with minimal energy difference regarding the oxidative addition. 
Figure IV-5 IV.16
B Scheme IV–2 IV.21
IV.16 
IV.4 IV.1








Figure IV-5: Energy diagram of the key bond making steps in the RuAAC 
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Figure IV-6: Commonly used [Cp*RuCl] for RuAAC purposes 
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Figure IV-7: Strain-promoted [3+2] azide-alkyne cycloaddition.  
IV.28
IV.29




Figure IV-8: Procedure for 1,4,5-trisubstituted triazole synthesis proposed by Akimova and further 
elaborated by Sharpless and Fokin. 
Figure IV-9 IV.33
IV. Click Chemistry | 49 
IV.34
IV.15
Figure IV-9: Hlasta’s procedure for 1,5-disubstituted triazole moieties. 
IV.36 Figure IV-10
Figure IV-10: Fokin’s transition-metal-free procedure for 1,5-disubstituted triazole moieties 
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I.3 III.1 Figure V-1.
Figure V-1: Structural and electronic evaluation of a cis-amide bond versus the 1,5-regioisomer of a 1,2,3-
triazole moiety  
Figure V-2
V.2 V.1
Figure V-2: Fundamental concept of this research applying bioisosterism to 1,5-benzodiazepine-2,4-
diones V.1 








Figure V-3: Retrosynthetic approach toward desired scaffold molecule V.2 
V.5
V.6  V.7
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V.10 Figure V-4





















Figure VI-1: Coupling step of the amino acid (V.9) to Wang resin (V.3) 
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Figure VI-2: Commonly used carbodiimide based coupling reagents 
1. Mechanism 
a) Possible pathways upon activation 
VI.5 VI.6 
VI.7 VI.8






O VI.9 VI.7 B
VI.11
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Scheme VI–1: Possible pathways upon carboxylic acid activation with carbodiimides. 
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N N
N,N VI.15, E




Figure VI-3: Racemization via oxazolone formation 
Figure VI-4 via O
VI.22 VI.23
VI.24
Figure VI-4: Racemization via keto-enol tautomerization 
VI. Coupling | 61 
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Scheme VI–2: Coupling of VI.25 – VI.32 to Wang’s resin V.3 
Table VI-1: Coupling efficiency 
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Figure VII-1: Diazotransfer reaction step 
di-nitrogen-transfer





“After experiencing an explosion…” 
VII.1
Scheme VII–1.
Scheme VII–1: Common preparation of trifluoromethanesulfonyl azide (VII.1) proposed by Shiner 
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Scheme VII–3: Proposed conditions by Goddard-Borger for in solution diazotransfer 
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I.2.B.1
C. Optimization procedure towards a solid-phase diazotransfer 
reaction  
VII.11  





 VII.11 UN 
Recommendations on the Transport of Dangerous Goods VII.11
VII.11
VII.11
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Scheme VII–4: Synthesis of imidazole-1-sulfonyl azide hydrochloride (VII.11) 
1. Influence of the solvent system 
Scheme VII–5: Diazotransfer optimization procedure by employing different solvent systems. 
VI.36
VII.11





Table VII-1: Solvents applied in Scheme VII–5 and corresponding amine-to-azide conversions 









Table VII-1 1 3
2 et al.,






Table VII-2: Amine-to-azide conversion with increasing amount of water ratio in the solvent system 
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Figure VII-3: Graphical representation of the amine-to-azide conversion with varying THF/H2O ratios as 
solvent system. 
 Table VII-2 Figure VII-3 
Table VII-2 11
2. Influence of the base 
Scheme VII–6.
Scheme VII–6: Optimization of the diazotransfer procedure by employing different bases. 
VII. Diazotransfer | 75 








3. Influence of the amount of diazotransfer reagent VII.11, the 
base and the reaction temperature 
Scheme VII–7: Optimization of the diazotransfer procedure by employing different equivalents of VII.11 
and base 
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Table VII-4: Conditions applied in Scheme VII–7 and corresponding amine-to-azide conversion 





3 4 Table VII-4
4. Determination of the epimerization ratio during diazotransfer 
reaction 
VII.20-VII.23  Figure VII-4  
VI.25
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Figure VII-4: Synthesized tripeptides (VII.20-VII.23) 
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Scheme VII–8: Solid-phase synthesis of azidotripeptides (VII.24-VII.27) 
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Figure VII-5
L,L-VII.26 D,L-VII.27 via
Figure VII-5: Overview of the synthesized azidotripeptides (VII.24-VII.27) 
Figure VII-6 L,L-VII.26 D,L-VII.26
L,D-VII.26 D,D-VII.26 L,L-VII.26 D,L-VII.26
L,L-
VII.26 D,D-VII.26 D,L-VII.26 L,D-VII.26
L,L-VII.26 D,L-VII.26
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Figure VII-6: All possible stereoisomers which could be formed during a diazotransfer reaction. 
Figure VII-7
L,L-VII.26 D,L-VII.26 Figure VII-8
L,L-VII.26 
D,L-VII.26 L,D-VII.26








 DAD1 A, Sig=214,20 Ref=off (H:\TEMP\018-1801.D)
Figure VII-7: HPLC co-injection chromatogram of an artificial mixture of L,L-VII.26 and D,L-VII.26 
VII. Diazotransfer | 81 








 DAD1 A, Sig=214,20 Ref=off (H:\TEMP\016-1301.D)
Figure VII-8: HPLC chromatogram of the sole injection of  L,L-VII.26 




Scheme VII–9: Overview of the -amino acids submitted to a diazotransfer reaction 
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6. Recent and ongoing important developments 
a) Towards safety 
VII.36
Scheme VII–10: Synthesis of benzotriazole-1-sulfonyl azide (VII.36) 
b) Towards a higher efficiency 
VII.11
Table VII-2 4
c) Late stage optimization  
VII.11
Table VII-5
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Scheme VII–11: Late stage optimization protocol 
Table VII-5: Results of the late stage optimization protocol 
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Figure VIII-1: Aimed 1,5-regioselectivity during formation of the 1,2,3-triazole moiety 
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Scheme VIII–1: Possible formation of 1,4- and 1,5-regioisomer of the 1,2,3-triazole moiety upon RuAAC 
and thermal click reaction induced by elevated temperatures 
VIII. 1,3-Dipolar cycloaddition | 89 
Table VIII-1: Conditions applied in Scheme VIII–1 
entry 
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Scheme VIII–2: Revised reaction outcome after standard cleavage 
VIII.7
C. Test case: ring closure 
I.B.2
VIII.7
Figure VIII-3 Figure VIII-4




Figure VIII-3: Base-promoted cyclization/release 
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Scheme VIII–3: Test reactions towards base-promoted cyclization/release 
Table VIII-2: Base-promoted cyclization/release conditions 
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2. Acid-catalyzed cyclization/release 
via
VIII.7 Figure VIII-4
Figure VIII-4: Acid-catalyzed cyclization/release 
VIII.A
VIII.5
Scheme VIII–4: Test reactions towards acid-catalyzed cyclization/release 
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Table VIII-3: Acid-catalyzed cyclization/release conditions 
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Figure VIII-5: Crude LC-MS of VIII.7 upon cyclization/release with HOAc/CH2Cl2, (1/1) at room 
temperature for 24h. 
 
Figure VIII-6: Remaining resin content upon standard cleavage conditions with 95% TFA/H2O for 2h at 
room temperature after applying cyclization/release with HOAc/CH2Cl2, (1/1) at room temperature for 
24h. 
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D. Proof of principle library 
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VIII.12 VIII.16 Table VIII-4
Table VIII-4: Results of the proof of principle library for compounds VIII.12 – VIII.16 







Figure VIII-7: Proof of principle library members 
Figure VIII-8
Figure VIII-9
VIII. 1,3-Dipolar cycloaddition | 97 
Figure VIII-8: Optimized chiral separation of an artificial mixture of (S)-VIII.16 and (R)-VIII-16 
Figure VIII-9: Chiral chromatogram of (S)-VIII.16 under optimized conditions  
 
98 | Part 3: Results & Discussion  




Figure VIII-10: Proposed diversification of the aromatic moiety 




Scheme VIII–6: Retrosynthetic approach towards building block synthesis with extra substituents 
VIII.21 VIII.25
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Scheme VIII–7: Sonogashira cross-coupling reaction 
Table VIII-5: Results of the Sonogashira cross-coupling reaction 
entry starting product R2 R3 compound yield (%) 
1 VIII.21 VIII.26 
2 VIII.22 VIII.27 
3 VIII.23 VIII.28 
4 VIII.24 VIII.29 









Scheme VIII–8: Selective monoalkynylation during Sonogashira cross-coupling and leaving group 
capacity 
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VIII.33 VIII.37 Scheme VIII-9 .
Scheme VIII–9: TMS-deprotection step of VIII.26-VIII.30 
Figure VIII-11 Table VIII-6
VIII.33 VIII.37  Table VIII-6
Figure VIII-11: Overview of five new building blocks VIII.33 – VIII.37
Table VIII-6: Overview of five new building blocks VIII.33 – VIII.37 
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VIII-20 VIII.18 VIII.19
 VIII.38 
Scheme VIII–10: Possible indole VIII.38 formation
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Scheme VIII–11: Synthesis 2-ethynyl-4-methoxyaniline building block VIII.45 
2. Combinatorial synthesis 
VIII.33 VIII.37 VIII.45
Scheme VIII–12
Table VIII-7 Table VIII-13
VI.25 VI.27-VI.32
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Scheme VIII–12: Combinatorial synthesis towards incorporation of three diversity points. 
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Table VIII-7: Library members VIII.47 – VIII.51 based on glycine as -amino acid  






Figure VIII-12: Library members VIII.47 – VIII.51 based on glycine as -amino acid  
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Table VIII-8: Library members VIII.52 – VIII.57 based on L-phenylalanine as -amino acid  







Figure VIII-13: Library members VIII.52 – VIII.57 based on L-phenylalanine as -amino acid  
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Table VIII-9: Library members VIII.58 – VIII.62 based on L-serine as -amino acid  






Figure VIII-14: Library members VIII.58 – VIII.62 based on L-serine as -amino acid  
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Table VIII-10: Library members VIII.63 – VIII.67 based on L-tryptophane as -amino acid  









Figure VIII-15: Library members VIII.63 – VIII.67 based on L-tryptophane as -amino acid  
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Table VIII-11: Library members VIII.68 – VIII.72 based on L-leucine as -amino acid  






Figure VIII-16: Library members VIII.68 – VIII.72 based on L-leucine as -amino acid  
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Table VIII-12: Library members VIII.73 – VIII.78 based on L-valine as -amino acid  







Figure VIII-17: Library members VIII.73 – VIII.78 based on L-valine as -amino acid  
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Table VIII-13: Library members VIII.79 – VIII.82 based on L-lysine as -amino acid  





Figure VIII-18: Library members VIII.82 – VIII.85 based on L-lysine as -amino acid  
Table VIII-7 Table VIII-13 Figure VIII-12 Figure VIII-18
d et al.  
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 IX.5b Figure IX-2




Figure IX-3: Regioselectivity study for internal alkynes performed by Weinreb4 
 Table IX-1 2
6 3 7
9
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Table IX-1: Summary of the experiments performed by Weinreb4 


























V.6 via V.11 
V.10
Scheme IX–1: Retrosynthetic approach towards the introduction of a 1,4,5-trisubstituted 1,2,3-triazole 
moiety. 
Scheme IX–1
Figure IX-5 V.6 






Figure IX-5: Proposed building blocks V.6 
IX.13 – IX.16
IX.13 IX.15 IX.16 
IX.14
Scheme IX–2: Internal alkyne building block IX.13 – IX.16 synthesis 
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Table IX-2: Isolated yields for building blocks IX.13 – IX.16 





C. Test case: Synthesis of 1,4,5-trisubstituted triazole 
moiety  
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Scheme IX–3: Strategy to determine the ratio of regioisomers V.5 : IX.19 
V.5 IX.19
IX.C.1 IX.C.5
Table IX-3 Table IX-7
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1. Regioselectivity of the cycloaddition with IX.13 
 
Scheme IX–4: Regioselectivity test reactions for IX.13 after a reaction time of 6h 









Table IX-1  
1
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2. Regioselectivity of the cycloaddition with IX.14 
Scheme IX–5: Regioselectivity test reactions for IX.14 after a reaction time of 6h 







Table IX-4 IX.14 IX.13
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3. Regioselectivity of the cycloaddition with IX.15 
Scheme IX–6: Regioselectivity test reactions for IX.15 after a reaction time of 6h 









IX.13 IX.14 Table IX-3 Table IX-4
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4. Regioselectivity of the cycloaddition with IX.16 
Scheme IX–7: Regioselectivity test reactions for IX.16 after a reaction time of 6h 







Table IX-6 IX.16 
IX.31 Scheme 
IX–8 IX.31 
Scheme IX–9, Table IX-7
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Scheme IX–8: Synthesis of building block IX.31 
5. Regioselectivity of the cycloaddition with IX.31 
Scheme IX–9: Regioselectivity test reactions for IX.31 after a reaction time of 6h 





6. Proof of principle library 
VI.31
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Table IX-8
Table IX-8: Optimized conditions for 1,4,5-triazole moiety incorporation 





Scheme IX–10: Proof of principle library incorporating a 1,4,5-triazole moiety.  
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Table IX-9: Proof of principle library incorporating a 1,4,5-triazole moiety. 





Figure IX-6: Four initial obtained scaffold with a 1,4,5-triazole moiety. 
Table IX-9  Figure IX-6
IX.37
Scheme IX–10
 VI.28 t VI.27 
IX.23, IX.25, IX.29 IX.39-IX.41
IX.15
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Table IX-10: Extended proof of principle library incorporating a 1,4,5-triazole moiety. 







Figure IX-7: Extended proof of principle library incorporating a 1,4,5-triazole moiety. 
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IX–11 Table IX-11 IX.42 IX.47
Scheme IX–11: Internal alkyne building block IX.42 – IX.47 synthesis 
Table IX-11: Isolated yields for building blocks IX.42 – IX.47 


















Scheme IX–12:  Synthesis of IX.51 
Scheme IX–13: Synthesis of IX.54 
Table IX-12  Table IX-15 Figure IX-8 Figure IX-11
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Scheme IX–14: Synthesis scheme for a combinatorial library incorporating a 1,4,5-triazole moiety. 
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Table IX-12: Library members IX.56 – IX.62  based on IX.42 as building block (R3 = H) 









Figure IX-8: Library members IX.56 – IX.62  based on IX.42 as building block 
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Table IX-13: Library members IX.63 – IX.69  based on IX.43 as building block (R3 = H) 









Figure IX-9: Library members IX.63 – IX.69  based on IX.43 as building block 
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Table IX-14: Library members IX.70 – IX.76  based on IX.45 as building block (R3 = H) 









Figure IX-10: Library members IX.70 – IX.76  based on IX.45 as building block 
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Table IX-15: Library members IX.77 – IX.80  based on IX.46-IX.47, IX.51 and IX.54 as building block 





Figure IX-11: Library members IX.77 – IX.80  based on IX.46-IX.47, IX.51 and IX.54 as building block 
Table IX-12  Table IX-15 IX.56 – IX.80
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Figure X-1: Bioisosteric replacement of a benzene moiety for a pyridine ring. 
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B. Building block synthesis 
d f X.1
X.6 – X.9
X.2 – X.3 
Scheme X-1 Scheme X-
2  
X.6 – X.7
Scheme X–1: Synthesis of 3-ethynyl-2-aminopyridine building blocks. 
Table X-1: Results for the synthesis of synthesis of 3-ethynyl-2-aminopyridine building blocks. 






Scheme X–2: Synthesis of 3-alkynyl-2-aminopyridine building blocks X.8 – X.9. 
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C. Proof of principle library 
X.6  X.9




Scheme X–3: Proof of principle library for the synthesis of [1,2,3]triazolo[1,5-d]pyrido[3,2-
f][1,4]diazepin-2-ones 
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Table X-2 Figure X-2
d VIII.D.2
Table X-2: Results for the proof of principle library presented in Scheme X-3 
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Figure X-3: Stabilization of protonated 2-aminopyridine derivative X.17 
X.19 X.20 Figure X-
4 X.21
via p
Figure X-4: Alternatives for 2-aminopyridine X.17 aiming an acid-catalyzed cyclization/release strategy
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Figure XI-1: N-alkylation step 
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Scheme XI–1: Retrosynthetic approach for the Mitsunobu-Fukuyama alkylation procedure. 
XI. N-alkylation 145 








Figure XI-2: Possible nosyl- and tosyl-based protecting group and corresponding standard deprotection 
methods for tertairy amines. 
  
Scheme XI–2: Nosyl protection of VIII.3 
Table XI-1 VIII.3
o 1 p 2
3
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Scheme XI–3: o-Nosyl protection of VIII.3 
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1 3 Table XI-2
XI.7
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XI.C







XI.15 XI.16 XI.12 XI.15
N XI.17
XI.16
XI. N-alkylation 149 
Scheme XI–4: Mitsunobu-Fukuyama N-alkylation mechanism 
b) Test cases 
o 12 Table 
XI-2
XI.7 (Scheme XI-5)
Table XI-3 Figure XI-3 N
XI.18 XI.20 XI.7
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Scheme XI–5: Mitsunobu-Fukuyama N-alkylation 
Table XI-3: Obtained conversion after repetitive Mitsunobu-Fukuyama alkylation 
entry ROH 




Figure XI-3: Progress of the Mitsunobu-Fukuyama alkylation for each alkylation cycle. 
Figure XI-3 1 2
3
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Scheme XI–6: Nosyl deprotection mechanism 
b) Test cases 
Scheme XI–7 XI.18 XI.20
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Scheme XI–7: Nosyl deprotection 










Scheme XI–8: Cyclization/release of N-alkylated secundary amines 
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Table XI-4: Conditions applied in Scheme XI–8 
entry compound conditions result (%)a 
1 XI.28 XI.31 XI.28
2 XI.29 XI.32 XI.29












C. Mitsunobu-Fukuyama: Second strategy 
o
N
XI.34  VIII.3 XI.34
Scheme XI–9
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Scheme XI–9: Synthesis of XI.34 




Scheme XI–10: Introducing o-Ns group on solid-phase via RuAAC 









A: VII.31 XI.7 XI.35
Table XI-5 1 VII.31
XI.35 XI.7






D. Mitsunobu-Fukuyama approach: Preliminary 
conclusion 
E. Second approach: Reductive alkylation 
1. Retrosynthesis 
Scheme XI–11 N via
XI.36
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Scheme XI–11: Retrosynthetic approach for the reductive alkylation procedure. 
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Scheme XI–12: Reductive alkylation with benzaldehyde 













Table XI-6 1 3 4 6
7 9 XI.38
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3. Scope of the reductive alkylation 
XI.E.2
Scheme XI–13: Scope of the reductive alkylation 
Scheme XI–13
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Scheme XI–14
Scheme XI–14: Reductive alkylation - acetaldehyde 















4. Test case: Cyclization/release of N-benzylated precursors 
XI.E.2
XI.38
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XI.51,
XI.52 Scheme XI–15
Scheme XI–15: Cyclization/release test reaction for XI.38 
Table XI-8: Cyclization/release test reaction for XI.38 - Conventional heating 
entry conditions 




2 XI.51  XI.52
3 XI.51  XI.52
4 XI.51  XI.52
5  XI.52

















Table XI-9: Cyclization/release test reaction for XI.38 - Microwave heating 
entry conditions 









5. Test case: Cyclization/release of ethylated compounds 
XI.39,
XI.E.4 Scheme XI–16).
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Scheme XI–16: Cyclization/release test reaction for XI.39 
Table XI-10: Cyclization/release test reaction for XI.39 – Conventional heating 
entry conditions 
crude purity of 
XI.53 (%)a 
remarks 









 Table XI-11 Figure XI-4
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Scheme XI–17: Synthesis scheme for solid-phase reductive alkylation   
Table XI-11: Results for the proof of principle library presented in Scheme XI-17 
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XI.5.F
 
Figure XI-4: Proof of principle library after employing a reductive alkylation strategy 




Figure XI-5: Three concerning resin-types and their standard cleavage conditions.   
N via
Scheme XI–18
Table XI-12 Table XI-13
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Scheme XI–18: N-Alkylation strategies employed on HMPS resin 
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Table XI-12: Cyclization/release test reaction for XI.66 – Conventional heating 
entry 
conditions crude purity of 
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Table XI-13: Cyclization/release test reaction for XI.66 and XI.64 – Microwave heating 













Scheme XI–19: Cyclization/release test reactions for XI.25 – XI.27 – Microwave heating 
Table XI-14: Conditions applied in Scheme XI–19 
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G. N-alkylation: Critical overview/review 
Scheme XI-20





Pathway B Scheme XI-20
N XI.38 - XI.39
XI.38 XI.39
XI. N-alkylation 169 
Scheme XI–20: General overview of the attempts towards N-alkylation 
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via
N IX.1
H. Third approach: N-alkylation in solution 
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Table XI-15: Members of the proof of principle library 
















Figure XI-6: Members of the proof of principle library 
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Figure XI-7: Members of the proof of principle library 
Table XI-16: Degree of racemization upon N-alkylation in solution 
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2. Combinatorial synthesis 
IX.C.7
Scheme XI–22: General N-alkylation procedure 
n
IX.C.7
Table XI-17 Table XI-18
Figure XI.8 Figure XI-9.
Table XI-17: Library members XI.76 – XI.83 
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Figure XI-8: Library members XI.76 – XI.83 
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Figure XI-9: Library members XI.84 – XI.91 
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Table XI-18: Library members XI.84 – XI.91 










IX.77 XI.92 Table XI-19, Figure XI-10
Table XI-19: Library members XI.92 – XI.93 
entry compound alkylation yield (%)  overall yield (%) 
1 XI.92 
2 XI.93 
Figure XI-10: Library members XI.92 – XI.93 
 Table XI-17 Table XI-18 Figure XI-8 Figure XI-9
N
N
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Figure XII-1: Structural and electronic evaluation of a cis-amide bond versus the 1,5-regioisomer of a 
1,2,3-triazole moiety 





Figure XII-2: General representation of our research 
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B. Coupling 
VI.25-VI.32, Scheme XII-1 O
VI.C
Scheme XII-1: Overview of the -amino acids coupling reaction on Wang resin 
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C. Diazotransfer  
VII.11
VII.11 Scheme XII-2




XII. Conclusions and future perspectives | 183 
Scheme XII-3: Overview of the resin-bound -amino acids submitted to a diazotransfer reaction 
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Scheme XII-4: RuAAC followed by ‘cyclization/release’ yielding VIII.7 
VIII.2
VIII.33 – VIII.37 via
Scheme XII-5, Table XII-1  
 VIII.45  
Scheme XII-6).
Scheme XII-5: Synthesis of 2-ethynylaniline building blocks VIII.33 – VIII.37 
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Scheme XII-6: Synthesis 2-ethynyl-4-methoxyaniline building block VIII.45 
Table XII-1: Overall yields of 2-ethynylaniline building block VIII.33 – VIII.37 and VIII.45 







VIII.33 – VIII.37 VIII.45 
VIII.47-VIII.82.  VIII.2
ad hoc
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Scheme XII-7: Combinatorial synthesis 
Table VIII-7 – VIII-13,
Figure XII-3
Figure XII-3: Selected compounds indicating trends towards cyclization/release  
post
XII. Conclusions and future perspectives | 187 
VIII.47-VIII.82
IX.13 – IX.16  IX.31  IX.42 – IX.47 via
IX.51
IX.54
Scheme XII-8: Standard Sonogashira cross-coupling procedure 
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Table XII-2: Overall yields of 2-alkynylaniline building blocks IX.13 – IX.16, IX.31, IX.42 – IX.47, IX.51 and 
IX.54 

















IX.42 - IX.43, IX.45 - IX.47, IX.51  IX.54
IX.44
XII. Conclusions and future perspectives | 189 
Scheme XII-10 
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E. Bioisosteric replacement 
X.6-X.9
X.11 X.15, Figure XII-4
XI.F. 
Table XII-3: Overall yields for 3-alkynyl-aminopyridine X.6-X.8 building blocks 







Figure XII-4: [1,2,3]triazolo[1,5-d]pyrido[3,2-f][1,4]diazepin-2-ones: proof of principle library results




via  XI.B  XI.C via
 XI.D
N
Pathway A Scheme XII-11
o
Scheme XII-11: Mitsunobu-Fukuyama strategy aiming N-monoalkylation on solid-phase 
Pathway B Scheme XII-12  
N
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Scheme XII-13: N-alkylation in solution-phase 
G. Recent literature report 
d V.2. 
XII.1-XII.5 Scheme XII-14 Table XII-4
XII. Conclusions and future perspectives | 193 
Scheme XII-14: In solution synthesis of [1,2,3]triazole[1,5-d]benzo[1,4]diazepines XII.1-XII.5 reported by 
Molteni 
Table XII-4: Results for a in solution synthesis of [1,2,3]triazole[1,5-d]benzo[1,4]diazepines XII.1-XII.5 
obtained by Molteni 








H. Future perspectives 
in vitro Figure XII-3  Figure 
XII-4
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XIV. Coupling 
A. Coupling of Fmoc-AA-OH to Wang resin V.3 
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A. Synthesis of imidazole-1-sulfonyl azide hydrochloride 
(VII.11) 
 VII.14  VII.11 
 









B. Optimization procedure: diazotransfer reaction  
1. Influence of the solvent 














Table XV-1: Solvent conditions optimization procedure 
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Table XV-2: Concentration standard solutions CuSO4.5H2O in MeOH (entry 1) or H2O (entries 2-11) 
2. Influence of the base 




Solution CuSO4.5H2O in MeOH (100 mL) 
1 
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Cleavage: in vacuo
3. Influence of equivalents of diazotransfer reagent VII.11, base 
and reaction temperature  
 VI.36  VII.10 
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Table XV-3: Conditions optimizing equivalents of VII.11 and reaction temperature 





4. Determination of epimerization during diazotransfer reaction 





XV. Diazotransfer 211 















Cleavage: in vacuo L,L-VII.26 D,L-
VII.26 



















































































C. Recent and ongoing important developments 
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Cleavage:

XVI. 1,3-Dipolar cycloaddition 
A. Test reactions for introducing 1,5-disubstituted 1,2,3-
triazole moiety 
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B. Base-catalyzed cyclization/release  








 VIII.3  VIII.7  







C. Acid-catalyzed cyclization/release 
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Table XVI-2: Acid-catalyzed cyclization/release test reactions 
Solution TFA HOAc CH2Cl2 DCE 
1 
2 















224 | Part 4: Supporting Information  

























XVI. 1,3-dipolar cycloaddition | 225 






(S)-3-(tert-Butoxymethyl)[1,2,3] triazolo[1,5-d][1,4]benzodiazepin-2-one VIII.14 
 
VIII.14 
























J J J J J
13C NMR
































LC-(ESI)MS tR  Purity
HRMS (ESI)
228 | Part 4: Supporting Information  
E. Sonogashira cross-coupling reaction 









Red-brown oil.  
RF:
Molecular weight:













Red-brown oil.  
RF:
Molecular weight:











Red-brown oil.  
RF:
Molecular weight:
1H NMR d  J 
J J 
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13C NMR d
HATR







Light yellow solid.  
RF:
Molecular weight:













Bright yellow solid. 
Rf:
Molecular weight:




LC-(ESI)MS tR  Purity
HRMS (ESI)
F. Deprotection of TMS group 
 VIII.26 – VIII.30  VIII.33 – VIII.37  














1H NMR d  J =









Yield: VIII.34  
Overall yield: 
Light-yellow solid.  
RF:
Molecular weight:
1H NMR d  J 
J J 
13C NMR d










Light-yellow solid.  
RF:
Molecular weight:












Light brown solid.  
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Rf:
Molecular weight:












Yellow solid.  
RF: 
Molecular weight:




LC-(ESI)MS tR  Purity
HRMS (ESI)
3-iodo-4-nitrophenol VIII.43 
 VIII.39  VIII.40  
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VIII.39
Yield: VIII.40
Brown solid.  
RF:
Molecular weight: 
1H NMR d J J J 
13C NMR d
HATR
LC-(ESI)MS tR  Purity
HRMS (ESI)
2-Iodo-4-methoxy-1-nitrobenzene VIII.42 





Yield: VIII.42   










 VIII.42  VIII.43  
P.06 VIII.42
Yield:  VIII.43
Light-brown crystalline solid.  
RF:
Molecular weight:






 VIII.43  VIII.44  












LC-(ESI)MS tR  
HRMS (ESI)
4-methoxy-2-ethynylaniline VIII.45 
 VIII.44  VIII.45  
P.07 VIII.44
Yield: VIII.45
Yellow solid.  
RF:
Molecular weight:
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RF:   
Mp:
Molecular weight:
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RF
Molecular weight:






























RF:   
Molecular weight: 225.21 Da.













RF:   
Molecular weight: 
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P.01 - P.05 S
d VIII.54
Yield:
White solid.  
RF:
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Molecular weight:









P.01 - P.05 S
d VIII.55
Yield:






























P.01 - P.05 S
d VIII.57
Yield:
White solid.  
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RF:
Molecular weight:




























P.01 - P.05 S
d VIII.59
Yield:
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1H NMR d









P.01 - P.05 (S)-
d VIII.61
Yield:
Light-brown solid.  
RF:
Molecular weight:
1H NMR d J J




HRMS (ESI)  
  












1H NMR d J = J =










P.01 - P.05: S - N
d VIII.63
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Yield:
White solid.  
RF:
Molecular weight:
1H NMR d J = J =




LC-(ESI)MS tR  Purity





P.01 - P.05: S N
d VIII.64
Yield:




1H NMR d J = J =
J = J =
J = J =
13C NMR d
HATR















1H NMR d J = J =
J = J = J 
= J = 
13C NMR d
HATR
LC-(ESI)MS tR   Purity
HRMS (ESI)
  












1H NMR d J = J =

















Molecular weight:   













P.01 - P.05: S
d VIII.68
Yield:
Light-brown solid.  
%ee:
RF:   
Mp:
Molecular weight:
1H NMR d J = J = J =









P.01 - P.05: S
d  VIII.69
Yield:
Light-brown solid.  
RF:
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Mp:
Molecular weight:
1H NMR d J = J = J =









P.01 - P.05: S
d VIII.70
Yield:  
















P.01 - P.05: S
d VIII.71  
Yield:




1H NMR d J = J = J =





 (S)-3-isobutyl-8-nitro[1,2,3]triazolo[1,5-d][1,4]benzodiazepin-2-one VIII.72 
 
VIII.72 
P.01 - P.05: S
d VIII.72
Yield:
White solid.  
RF:
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Mp:
Molecular weight:
1H NMR d J = J = J =









P.01 - P.05: S
d VIII.73
Yield:
White solid.  
RF:
Mp:   
Molecular weight: 
1H NMR d J J =










P.01 - P.05: S
d VIII.74
Yield:
White solid.  
RF:
Mp:   
Molecular weight: 276.72 Da.  
1H NMR d J = J =
J = J = J = J =
13C NMR d
HATR
LC-(ESI)MS tR   Purity
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Mp:
Molecular weight:
1H NMR d J = J =













1H NMR d J J






XVI. 1,3-dipolar cycloaddition | 259 
(S)-3-isopropyl-8-nitro[1,2,3]triazolo[1,5-d][1,4]benzodiazepin-2-one VIII.77  
 
VIII.77 
P.01 - P.05: (S
d VIII.77
Yield:
Light-brown solid.  
RF:
Molecular weight:   
1H NMR d J = J =






 (S)-3-isopropyl-8-methoxy[1,2,3]triazolo[1,5-d][1,4]benzodiazepin-2-one VIII.78 
 
VIII.78 
P.01 - P.05 S d
 VIII.78
Yield: 
Light-yellow solid.  
RF: 
Molecular weight: 
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P.01 - P.05 S
d VIII.79
Yield:





J = J = J =
J = J =
13C NMR d
HATR
XVI. 1,3-dipolar cycloaddition | 261 
LC-(ESI)MS tR  
Purity











Molecular weight:   
1H NMR d
J = J =













P.01 - P.05: (S)
d VIII.81
Yield:

















P.01 - P.05: (S)-
d VIII.82
Yield:









LC-(ESI)MS tR  Purity
HRMS (ESI)

XVII. Synthesis of 1,4,5-
trisubstituted triazoles 










1H NMR d  J J
J J J 
J 
13C NMR d  
HATR 
LC-(ESI)MS tR Purity








Light-yellow viscous oil. 
Molecular weight:  
RF:
1H NMR d  J
J J J
  








XVII. Synthesis of 1,4,5-trisubstituted triazoles| 267 
P.06
Yield: IX.15
Light-brown reddish viscous oil.  
Molecular weight:
RF:
1H NMR d  
J J J
J   
13C NMR d
HATR











1H NMR d   J
J J J
13C NMR d




B. Regioselectivity of IX.13 in RuAAC 
 


















C. Regioselectivity of IX.14 in RuAAC 
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D. Regioselectivity of IX.15 in RuAAC 
 











E. Regioselectivity of IX.16 in RuAAC 
 
 VII.31  IX.29  IX.30  

















Yellow crystals.  
RF:
Molecular weight:
1H NMR d  
HATR
LC-(ESI)MS tR Purity
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F. Regioselectivity of IX.31 in RuAAC 
 














XVII. Synthesis of 1,4,5-trisubstituted triazoles| 273 






d  IX.35  
Yield: 
Brown solid.  
Molecular weight: 
RF: 




LC-(ESI)MS tR Purity 
HRMS (ESI)
  





P.01 P.03, P.08  P.05 S





1H NMR d  
J J
J J   
13C NMR d
HATR
LC-(ESI)MS tR Purity 
HRMS (ESI)
  
















LC-(ESI)MS tR Purity 
HRMS (ESI)
  





P.01 P.03, P.08  P.05 S















XVII. Synthesis of 1,4,5-trisubstituted triazoles| 277 
P.01 P.05 S
d  IX.23   
Yield:
Brown solid.  
Molecular weight:
RF:









P.01 P.03, P.08  P.05 S





1H NMR d  
13C NMR d  








P.01 P.03, P.08  P.05 S





1H NMR d  














d  IX.39  
 
Yield:
Brown solid.  
Molecular weight:
RF:












P.01 P.03, P.08  P.05 S
d IX.40  
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Yield:
Brown oil.  
Molecular weight:
RF:











P.01 P.03, P.08  P.05 S
d IX.41  
 
Yield: 
Brown solid.  
Molecular weight: 
RF: 
1H NMR d  
J
13C NMR d













1H NMR d  J J
J J J 












Yellow oil.  
Molecular weight:
RF:   
1H NMR d  J J
J J J 













XVII. Synthesis of 1,4,5-trisubstituted triazoles| 283 
1H NMR d  J J
J J J 
 










Yellow solid.  
Molecular weight:
RF:














Yellow solid.  
RF:
Molecular weight:












XVII. Synthesis of 1,4,5-trisubstituted triazoles| 285 
Yellow solid.  
Molecular weight:  
RF:










Greenish oil.  
Molecular weight: 
RF: 
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Yellow oil.  
Molecular weight:
RF:
1H NMR d  J J
J J J














Red oil.  
Molecular weight: 
RF:













Yield: IX.52  
RF:
White crystals.  
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Molecular weight:
1H NMR d  
J J
J













Light-red oil.  
Molecular Weight: 
RF: 
1H NMR d   J
J J
13C NMR d  
HATR








Yellow oil.  
Molecular weight:
RF:
1H NMR d  J J
J J
J
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 IX.56  
Yield:
White solid.  
Molecular weight:
RF:











d IX.57  
XVII. Synthesis of 1,4,5-trisubstituted triazoles| 291 
Yield: 
Light-brown solid.  
Molecular weight: 
RF: 


















1H NMR d  J J
J J J
13C NMR d





















HRMS (ESI)   






d IX.60  
Yield:
White solid.  
Molecular weight:
RF:











d  IX.61  
Yield:
White solid.  
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Molecular weight:
RF:












P.01 P.05 S N
d IX.62
Yield: 
White solid.  
Molecular weight
RF: 













d  IX.63, 
Yield:
Light-brown solid.  
Molecular weight:
RF:





































1H NMR d  J J
J J










P.01 P.05 S N






1H NMR d  J 
J












d  IX.67,  
Yield:
Light-brown solid.  
Molecular weight:
RF:













d  IX.68,  
Yield:
Light-yellow solid.  
Molecular weight:
RF:
1H NMR d  J J
J
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P.01 P.05 S N





1H NMR d  J





HRMS (ESI)  
(S)-8-chloro-6-(2-hydroxyethyl)-3-methyl[1,2,3]triazolo[1,5-d][1,4]benzodiazepin-2-





d  IX.70,   
Yield:
Light-brown solid.  
Molecular weight:
RF:




XVII. Synthesis of 1,4,5-trisubstituted triazoles| 301 
HATR
LC-(ESI)MS tR  Purity  
HRMS (ESI)  
(S)-3-benzyl-8-chloro-6-(2-hydroxyethyl)[1,2,3]triazolo[1,5-d][1,4]benzodiazepin-2-




























1H NMR d  








XVII. Synthesis of 1,4,5-trisubstituted triazoles| 303 
P.01 P.05 S N










13C NMR d  
HATR
LC-(ESI)MS tR Purity






d  IX.74,  
Yield:
White solid.  
Molecular weight:
RF:
1H NMR d  J
J J
J





















HRMS (ESI)  
 






P.01 P.05 S N
d  IX.76, 
 
Yield:
Bright-yellow solid.  
Molecular weight:
RF:
1H NMR d  
J J
J




8-chloro-6-phenyl[1,2,3]triazolo[1,5-d][1,4]benzodiazepin-2-one IX.77  
 
IX.77 
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P.01 P.03, P.08  P.05










8-bromo-6-phenyl[1,2,3]triazolo[1,5-d][1,4]benzodiazepin-2-one IX.78  
 
IX.78 
P.01 P.03, P.08  P.05
d IX.78,  
Yield:
Light-brown solid.  
Molecular weight:
RF:
1H NMR d  J 
13C NMR d
HATR
XVII. Synthesis of 1,4,5-trisubstituted triazoles| 307 
LC-(ESI)MS tR Purity
HRMS (ESI)
(S)-6-butyl-8-methoxy-3-isopropyl[1,2,3]triazolo[1,5-d][1,4]benzodiazepin-2-one IX.79  
 
IX.79 
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(S)-6-butyl-9-methoxy-3-isopropyl[1,2,3]triazolo[1,5-d][1,4]benzodiazepin-2-one IX.80  
 
IX.80 
P.01 P.05  S
d IX.80
Yield:
Yellow oil.  
Molecular weight:
RF:
1H NMR d  J J J 
J
J




XVIII. Synthesis of [1,2,3]triazolo[1,5-
d][3,2-f]pyrido[1,4]diazepin-2-ones 







Yellow solid.  
Molecular weight:
RF: 
1H NMR d   J











Light-yellow solid.  
Molecular weight:
RF:
1H NMR d  J = 
J =









Overall yield:  
Light-brown solid.  
RF:
XVIII. Synthesis of [1,2,3]triazolo[1,5-d][3,2-f]pyrido[1,4]diazepin-2-ones | 311 
Molecular weight:
1H NMR d  J = 











Light-yellow solid.  
Molecular weight:
RF






2-amino-3-hexynylpyridine X.8  
 
X.8 
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P.06
Yield: X.8
Dark-red oil.  
Molecular weight:
RF:










Yellow solid.  
Molecular weight:
RF:




XVIII. Synthesis of [1,2,3]triazolo[1,5-d][3,2-f]pyrido[1,4]diazepin-2-ones | 313 
HRMS (ESI)










1H NMR d  J 








P.01 – P.05 S N
d f  X.12
















P.01 – P.05 S d
f  X.13   
Yield:  
White solid.  
RF:   
Molecular weight:  








XVIII. Synthesis of [1,2,3]triazolo[1,5-d][3,2-f]pyrido[1,4]diazepin-2-ones | 315 
(S)-6-butyl-3-isobutyl[1,2,3]triazolo[1,5-d][3,2-f]pyrido[1,4]diazepin-2-one X.14  
 
X.14 
P.01 – P.05 S d





1H NMR d  
J
J





P.01 – P.05 S d
f  X.15   
Yield: 
White Solid.  
Molecular weight: 
RF: 
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1H NMR d   





A. First approach: Mitsunobu-Fukuyama alkylation 








VIII.3 via P.01 P.04
VIII.3 Table XIX-1  Table XIX-2
Table XIX-1  Table XIX-2
Table XIX-1 and Table XIX-2 Table XIX-1 and 
Table XIX-2 Table XIX-1 and Table XIX-2
in 
vacuo










XIX. N-alkylation| 319 
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Table XIX-2: Various conditions for Nosyl protection (amounts) 
XIX. N-alkylation| 321 
2. Introduction of o-Nosyl group 
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3. Mitsunobu-Fukuyama alkylation 









 XI.7  XI.19  
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B. Mitsunobu-Fukuyama: Second strategy 
1. Solution-phase synthesis of XI.37 
 VIII.2  XI.34  
 
o







1H NMR d J 
13C NMR d
LC-(ESI)MS tR Purity:
2. Click-reaction of XI.37 with VII.31 




VII.31   XI.34
in vacuo

















C. Second approach: Reductive alkylation 
1. Reductive alkylation - benzaldehyde 
 VIII.3  XI.38  
VIII.3 via P.01 P.04
XI.38 Table XIX-3
Table XIX-3
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2. Scope of the reductive alkylation 
Scheme XIX-1: Scope of the reductive alkylation 
P.12 VIII.3
P.01 P.04 Table XIX-4
XIX. N-alkylation| 331 














3. Test case: Cyclization/release of N-benzylated precursors 
 XI.38  XI.51 XI.52  
XI.38 via P.12 
Table XIX-5
Table XIX-5
1 8 9 11 14 16
12 13
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4. Optimization procedure for acetaldehyde 
 VIII.3  XI.39  
VIII.3 P.01 P.04
Table XIX-6 Table XIX-6
XIX. N-alkylation| 333 
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5. Test case: Cyclization/release of N-ethylated precursors  
 XI.39  XI.53 XI.54  










 XI.55-XI.56  XI.51 XI.53 XI.57 XI.58  
P.14
via P.01 P.04 P.12 P.13. 
XIX. N-alkylation| 335 










1H NMR d   J
13C NMR d
LC-(ESI)MS tR Purity
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D. Solid-phase synthesis using HMPS resin 
1. Synthesis of XI.66 on HMPS resin 




























2. Cyclization/release on HMPS-resin for intermediate XI.66 
 XI.66  XI.51  
 
XI.66
Table XIX-8 1 5
6 12
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1 – 5
6 – 9 12
10














3. Synthesis of XI.65 on HMPS resin and cyclization/release 








XIX. N-alkylation| 339 
Cleavage: XI.64
E. Third approach: N-alkylation in solution-phase 
1. N-alkylation in solution-phase 
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Molecular weight:
1H NMR d 278K   
1H NMR d 298K   
1H NMR d 313K   
13C NMR d 298K
HATR 
LC-(ESI)MS tR Purity










1H NMR d 223K   J
J  J 
1H NMR d 298K   J
J  J 
XIX. N-alkylation| 341 
1H NMR d 328K  
13C NMR d 298K
HATR 
LC-(ESI)MS tR Purity










1H NMR d   J J
J













Yield: d XI.73  
Overall yield: 
White solid.  
RF:
Molecular weight:








XIX. N-alkylation| 343 
P.15 (S)- d
(S)-VIII.16
Yield: (rac)- d (rac)-
XI.28
Overall yield:  
White solid.  
Molecular weight:
RF:












Yield:  (rac)- d (rac)-
XI.29
Overall yield:  
White solid.  
Molecular weight: 
RF:
1H NMR d  J J 
JAX JBX JAB















Yield: (rac)- d (rac)-
XI.30




1H NMR d   J J
J J JAX JBX JAB
JAX JBX JAB J
J J J
XIX. N-alkylation| 345 
J J








P.15 (S)- - d
(S)-VIII.16
Yield: (rac)- d (rac)-
XI.74




1H NMR d  J
J













Yield: rac)- d (rac)-
XI.75
Overall yield:  
White solid.  
Molecular weight:
RF:
1H NMR d  
J














White solid.  
Molecular weight:
RF:




















White solid.  
Molecular weight:
RF:










































White solid.  
Molecular weight:
RF:






















White solid.  
Molecular weight:
RF:
1H NMR d  J 
J
J J

















White solid.  
Molecular weight:
RF:
1H NMR d  J 
J
J J

























13C NMR (125 MHz, acetone-d6)  









P.15  (S) N
d IX.66












13C NMR (125 MHz, acetone-d6)  
















1H NMR d  
 J
J  J 
13C NMR d

















1H NMR d  
 J







































1H NMR d  J J 
J J 




















White solid.  
Molecular weight:
RF:


















White solid.  
Molecular weight:
RF:



















White solid.  
Molecular weight:
RF:









































1H NMR d    
J 













White solid.  
Molecular weight:
RF:
1H NMR d    
J J  J













Figure XX-1: Thalidomide (XX.1) and perhexiline (XX.2) enantiomers 
368 | Part 5: Appendix  
XX.4 Figure XX-2
“conformers which, owing to steric or electronic constraints, interconvert 





Figure XX-2: Difference between classical enantiomers and atropisomers 
Figure XX-
3
Figure XX-3: Classification of atropisomers based on torsion rotation energy barrier 
atropos
Atropisomerism | 369 
in vivo
XX.5 Figure XX-4
and other diseases 
such as Crohns disease
XX.5
XX.6 Figure XX-4
Figure XX-4: Laquinimod (XX.5) and Afloqualone (XX.6) 
XX.8
N XX.7





Figure XX-5: N-desmethyldiazepam (XX.7) and diazepam (XX.8) 
Table XX -1: Ring inversion energy barriers 
 












Table XX-2: Half-life times for different free Gibbs activation energies in function of the absolute 
temperature 
 
G  [kcal/mol] 
12 17.6 21.1 24 
Table XX-2
B. Dynamic NMR studies 









Figure XX- 7: Compound XI.57 and illustration of possible atropisomers 
Figure XX-8 XI.57
via
Atropisomerism | 373 
Figure XX- 8: Full 1H NMR spectrum indicating strongly broadened signals for Ha and Hb (acetone-d6, 
298K, 300 MHz) 
Figure XX-8
Figure XX- 9: NMR spectra at different temperatures for compound XI.57 (acetone-d6, 500MHz) 







Figure XX- 10: Full and detailed 1H spectra for XI.65 and XI.72 (acetone-d6, 298K, 500MHz) 
Atropisomerism | 375 
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Figure XXI.1 Figure XXI.2,
Figure XXI.3
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Figure XXI.1: Full 1D spectrum (500 MHz) Figure XXI.2: Full C13 APT spectrum (176 MHz) 
XXI. NMR Case Study | 379 
 
Figure XXI.3: Full 2D TOCSY spectrum with annotation of the selected spin systems 
380 | Part 5: Appendix  
n
B. Spin system 1 






Figure XXI.4: Detail 1D NMR  aromatic spin system 
XXI. NMR Case Study | 381 
Label multiplicity ppm Integration 
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Figure XXI.6: Schematic representation of the aromatic region (7.60-7.85 ppm)
 Figure XXI.5 vide supra  
Figure XXI.7
 
Figure XXI.7: 2D HSQC detail related to the aromatic region
XXI. NMR Case Study | 383 





Figure XXI.8: Detail 1D NMR -H amino acid region 
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Figure XXI.9: Detail C13 APT 55-71 ppm Figure XXI.10: 2D HSQC detail related to -H 
amino acid region 
Figure XXI.11
Figure XXI.12 Figure XXI.13  
Figure XXI.14
 
XXI. NMR Case Study | 385 
Figure XXI.11: Detail 1D NMR 1.20-2.60 ppm 
Label multiplicity ppm Integration 
 
  
Figure XXI.12: 2D HSQC detail related to 9 and  
13 
Figure XXI.13: 2D HSQC detail related to 11 and 
13 
386 | Part 5: Appendix  
 
Figure XXI.14: Detail C13 APT related to region 9 - 11 
Figure XXI.12
Figure XXI.13
Figure XXI.15 Figure XXI.16
Figure XXI.16
Figure XXI.29 vide infra
XXI. NMR Case Study | 387 
Figure XXI.15: 2D COSY detail related to 4 and 
9-10 
Figure XXI.16: 2D COSY detail related to 9-10 and
11
Figure XXI.17
Figure XXI.17: Detail of region 9 and  proposed splitting pattern 
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Figure XXI.18
Figure XXI.18: Detail 1D NMR 0.70 – 1.05 ppm 
Label multiplicity ppm Integration 
Figure XXI.19 Figure XXI.22
Figure XXI.23
Figure XXI.19
XXI. NMR Case Study | 389 
Figure XXI.19: 2D HSQC detail related to  
region 15 - 16 
Figure XXI.20: 2D COSY detail correlation between 
region 11 and region 16 
Figure XXI.21: 2D HSQC detail related to  
region 14 - 16 
Figure XXI.22: 2D COSY detail correlation 
between region 14 – 16 and region 5 to 7 
390 | Part 5: Appendix  




Figure XXI.24: 2D COSY detail related to region 16 – 17 and region 13 
Figure XXI.25
XXI. NMR Case Study | 391 
Figure XXI.25: Schematic representation of splitting pattern in region 14 to 17 
multiplicity ppm integration annotation 
D. Spin system 3 
Figure XXI.26
Figure XXI.27 Figure XXI.28
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Figure XXI.26: Detail 1D NMR 3.60 – 4.25 ppm 
Label multiplicity ppm Integration 
Figure XXI.27: 2D HSQC detail related to region 5 
to 7  
Figure XXI.28: 2D COSY detail related to region 5 
to 7 and region 14 - 16 
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Figure XXI.29
Figure XXI.27 Figure XXI.28
 
Figure XXI.29: 2D TOCSY detail appointing three spin systems 
regarding the aliphatic region 
Figure XXI.30
Figure XXI.30: Schematic representation of the region 5 to 7 
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E. Spin System 4 
Figure XXI.29 vide supra
Figure XXI.31
Figure XXI.32 Figure XXI.37
Figure XXI.31: 2D COSY walkthrough related to spin system 4 
XXI. NMR Case Study | 395 
 
Figure XXI.32: 2D HSQC detail related to region 
13 
Figure XXI.33: 2D COSY detail related to region 
13 and region 16 
Figure XXI.34: 2D HSQC detail related to region 
12 
Figure XXI.35: 2D COSY detail related to region 
12 and region 13 
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Figure XXI.36: 2D HSQC detail related to region 8 Figure XXI.37: 2D COSY detail related to region 
12 and region 8 
 




XXI. NMR Case Study | 397 




Figure XXI.39: 2D HMBC detail related to 
quaternary carbons B and D 
Figure XXI.40: 2D HMBC detail related to 
quaternary carbons C - F 
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G. Overview  
 
label multiplicity range (ppm) integration annotation 
 
 
XXI. NMR Case Study | 399 
 
range (ppm) annotation range (ppm) annotation 
 

